Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tanner

Showing results (821-830 of 855) with videos related to

Pageof 86
Sort By:
Blood|April 25, 2012
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaAnn-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, et al.
Parkinsonism & Related Disorders|October 23, 2016
Knowledge gaps and research recommendations for essential tremorFranziska Hopfner, Dietrich Haubenberger, Wendy R Galpern, et al.
The British Journal of Dermatology|September 14, 2011
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboT Dirschka, P Radny, R Dominicus, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Cinpanemab in Early Parkinson's DiseaseAnthony E Lang, Andrew D Siderowf, Eric A Macklin, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
The British Journal of Dermatology|December 21, 2012
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosisT Dirschka, P Radny, R Dominicus, et al.
Cell Metabolism|December 10, 2019
Regulation of Tumor Initiation by the Mitochondrial Pyruvate CarrierClaire L Bensard, Dona R Wisidagama, Kristofor A Olson, et al.
Neurology|February 13, 2019
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseasesAlberto J Espay, Joaquin A Vizcarra, Luca Marsili, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
Pageof 86

Showing results (821-830 of 855) with videos related to

Sort By:
Pageof 86
Blood|April 25, 2012
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaAnn-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, et al.
Parkinsonism & Related Disorders|October 23, 2016
Knowledge gaps and research recommendations for essential tremorFranziska Hopfner, Dietrich Haubenberger, Wendy R Galpern, et al.
The British Journal of Dermatology|September 14, 2011
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placeboT Dirschka, P Radny, R Dominicus, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Cinpanemab in Early Parkinson's DiseaseAnthony E Lang, Andrew D Siderowf, Eric A Macklin, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
The British Journal of Dermatology|December 21, 2012
Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosisT Dirschka, P Radny, R Dominicus, et al.
Cell Metabolism|December 10, 2019
Regulation of Tumor Initiation by the Mitochondrial Pyruvate CarrierClaire L Bensard, Dona R Wisidagama, Kristofor A Olson, et al.
Neurology|February 13, 2019
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseasesAlberto J Espay, Joaquin A Vizcarra, Luca Marsili, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
Pageof 86